1 / 19

Principal Investigator: Dr. Kishor M. Wasan, Ph.D. Professor & Chair

Development of Novel Oral Lipid-Based Amphotericin B Formulations for the Treatment of Systemic Fungal Infections and Visceral Leishmaniasis. Principal Investigator: Dr. Kishor M. Wasan, Ph.D. Professor & Chair Distinguished University Scholar Faculty of Pharmaceutical Sciences

kylia
Download Presentation

Principal Investigator: Dr. Kishor M. Wasan, Ph.D. Professor & Chair

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Development of Novel Oral Lipid-Based Amphotericin B Formulations for the Treatment of Systemic Fungal Infections and Visceral Leishmaniasis Principal Investigator: Dr. Kishor M. Wasan, Ph.D. Professor & Chair Distinguished University Scholar Faculty of Pharmaceutical Sciences University of British Columbia Team Members: Dr. Ellen K. Wasan Dr. Sheila J. Thornton Dr. Karen Bartlett Mr. Ian Bell Dr. John Clement Workshop on Universities, Innovation and Global Medicine Access University of Toronto, Toronto, ON April 20th 2009

  2. Acknowledgments Research Faculty and Staff Dr. Kristina Sachs-Barrable Dr. Sheila Thornton Dr. Carlos Leon Dr. Pavel Gershkovich Ms. Olena Sivak Dr. Cheri Barta Dr. Robin Stoodley Mr. Mike Rosland Ms. Verica Risovic Current Graduate Students Jennifer Locke Stephen Lee Jackie Fleischer Caylee-Britt Goshko Alexis Twiddy Research Funding Canadian Institutes of Health Research (CIHR) Operating Grants AAPS Lipid-Based Drug Delivery Award/Grant National Cancer Institute of Canada- Clinical Trials Group (NCIC-CTG; MA.17) iCo Therapeutics Inc. CPDD Website http://www.wasanlab.ubc.ca Numerous Undergraduate Students Dr. Tom Kanyok (Gates Foundation)

  3. Journal of Pharmaceutical Sciences, Published On-line August 7th 2008

  4. Expert Opinion on Drug Delivery; Published March 2009

  5. Amphotericin B Mainstay of antifungal therapy for systemic mycoses Polyene antifungal drug discovered in 1955 Available in 4 formulations

  6. Demonstrated Efficacy Fungal infections Cryptococcosis Candidiasis Aspergillosis

  7. Candidiasis Oral cavity of an AIDS patient covered by white curdlike exudate containing numerous fungal organisms.

  8. Demonstrated Efficacy Parasitic infections Leishmaniasis Visceral Mucocutaneous Cutaneous

  9. “Real World” Efficacy 1.5 million new cases reported every year (WHO) Visceral leishmaniasis causes ~59 000 deaths annually

  10. Current Treatments of VL

  11. Implications for Developing Countries Parenteral administration results in: Loss of income Increased cost of administration Increased risk of side effects Decreased availability of treatment

  12. Overcoming Barriers to Treatment Oral route of administration Decreased toxicity Efficacious Thermal stability at tropical temperatures Stability – pH Affordability

  13. *P<0.05 vs. Control * * *

  14. Antifungal Activity Preliminary evidence shows efficacy against Candidiasis kidney gross morphology of an untreated and treated rat

  15. Antiparasitic ActivityLeishman-Donovan units (LDU)

  16. Antiparasitic Activity

  17. Antiparasitic Activity

  18. Advantages of Oral Amphotericin B Formulation • Affordable • Easy to store • Easy to administer • Lack of kidney toxicity • Lack of Infusion-related side effects (i.e. fever, chills etc.)

More Related